Calidi Biotherapeutics Plunges 8.12% Amid Market Volatility

On July 18, 2025, Calidi Biotherapeutics, Inc. (NYSE American: CLDI) experienced a significant drop of 8.12% in pre-market trading, reflecting investor concerns and market volatility.

Calidi Biotherapeutics, Inc. recently announced the exercise of warrants for $4.6 million in gross proceeds, which is expected to strengthen the company's financial position and support its ongoing research and development efforts. This move is part of Calidi's strategy to advance its RedTail platform, which aims to deliver genetic medicines to distal sites of disease. The company's CEO, Eric Poma, highlighted the transformative potential of this technology in addressing unmet medical needs.

Additionally, Calidi Biotherapeutics has been featured in various industry reports and news articles, underscoring its role in the biotechnology sector. The company's focus on genetic medicines and its innovative approaches have garnered attention from investors and industry experts alike. Despite the recent market fluctuations, Calidi remains committed to its mission of developing groundbreaking therapies that can improve patient outcomes.